Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot comparison of boric acid plus Lactobacillus vaginal capsules versus standard vaginal drugs in vulvovaginitis
2016-000371-24Phase 3Active
- Sponsor
- Laboratorios Ordesa
- Start
- Mar 2016
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of boric acid + lactobacillus gasseri + lactobacillus rhamnosus in bacterial vaginosis (BV), vulvovaginal candidiasis (VVC) and Vulvovaginitis (4 arms), sponsored by Laboratorios Ordesa. Primary endpoint: Symptom resolution at 2 weeks. Started Mar 2016; status: active.
02
Drugs
boric acid + lactobacillus gasseri + lactobacillus rhamnosus
03
Conditions
bacterial vaginosis (BV)vulvovaginal candidiasis (VVC)Vulvovaginitis
Beyond the preview
Go deeper on 2016-000371-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000371-24.